| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
CD161+CD8+ T cells in patients with hepatitis B virus-associated hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chen-Rui Liu, Meng Zhang, Mu-Qi Wang, Wen Zhang, Jin Li, Gao-Zhao Shi, Fan-Fan Liang, Ya-Ping Li and Na Huang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Basic and Clinical Integration Project of Xi’an Jiaotong University |
YXJLRH2022067 |
| Shaanxi Provincial Basic Research Program in Natural Sciences |
2023-JC-647 |
| Shaanxi Provincial Basic Research Program in Natural Sciences |
2023-JC-QN-0918 |
|
| Corresponding Author |
Na Huang, PhD, Biological Diagnosis and Treatment Center, Second Affiliated Hospital of Xi’an Jiaotong University, No. 157, Xiwu Road, Xincheng District, Xi'an City, Xi’an 710004, Shaanxi Province, China. huangna_428@163.com |
| Key Words |
CD8+ T cells; CD161; Programmed death receptor 1; Hepatitis B virus-associated hepatocellular carcinoma; Immunotherapy |
| Core Tip |
This study reveals elevated CD161+CD8+ T cells in peripheral blood of hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) patients, correlating with disease progression. Programmed death receptor 1 (PD-1) inhibitors reduced PD-1+ subsets but did not alter CD161 expression, indicating CD161 operates independently of PD-1 pathways. Critically, CD161 protein overexpression in HCC tissues—exceeding paracancerous and chronic hepatitis B tissues—identifies it as a key immunosuppressive molecule. These findings position CD161 as a promising standalone immunotherapeutic target for enhancing T-cell function in HBV-HCC, beyond current PD-1 blockade strategies. |
| Publish Date |
2026-04-08 07:28 |
| Citation |
Liu CR, Zhang M, Wang MQ, Zhang W, Li J, Shi GZ, Liang FF, Li YP, Huang N. CD161+CD8+ T cells in patients with hepatitis B virus-associated hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(4): 114547 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i4/114547.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i4.114547 |
